Medtech Vascular constant-currency sales growth measures revenue growth in Stryker's Vascular business after removing foreign-currency translation effects.
Stryker reported a 1.8% constant-currency decline in Vascular for the second quarter of 2026. Revenue was $496M, compared with $498M a year earlier.
U.S. weakness offset international growth
U.S. Vascular revenue declined 6.7%, while international revenue increased 4.0% on a constant-currency basis.
The consolidated decline therefore masks opposing regional trends.
Vascular revenue is not a procedure-volume index
The business includes products used to treat acute ischemic and hemorrhagic stroke and venous thromboembolism, and revenue can move with product and geographic mix.
Compare it with Endoscopy constant-currency sales growth and MedSurg and Neurotechnology operating margin.
Primary source: Stryker Q2 2026 Form 10-Q.
Part of the Medtech Product Family Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- SYKOpen operating-model research →10 of 10 reviewed concepts in Medtech Product Family EconomicsMedSurg and Neurotechnology product growth4 of 4 bridge concepts supportedContinue through this bridge:Endoscopy Constant-Currency GrowthInstruments Constant-Currency GrowthMedical Constant-Currency Growth
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare vascular growth
Compare Vascular growth while preserving opposing U.S. and international trends and product-mix effects.
Explore more topics in the Financial Research Encyclopedia.